Brief: Lee's Pharmaceutical Holdings Posts Qtrly Profit Attributable Of HK$71.7 Mln

Lees Pharmaceutical Holdings

29/11/2018 10:05

Nov 29 (Reuters) - Lee's Pharmaceutical Holdings Ltd
 0950.HK :
    * QTRLY REVENUE HK$299.2 MILLION VERSUS HK$275 MILLION
    * QTRLY  PROFIT ATTRIBUTABLE HK$71.7 MILLION VERSUS HK$61.8
MILLION
    * APPROVALS FOR TRAZODONE AND PRULIFLOXACIN ARE EXPECTED TO
BE
RECEIVED IN Q1 OF 2019.
    * LEE'S PHARMA HOLDINGS - CLINICAL STUDY ON NATULAN,
BIOEQUIVALENCE STUDY FOR AZILSARTAN COMPLETED; IDL SUBMISSIONS
EXPECTED BY END OF 2018.
    * RESEARCH AND DEVELOPMENT EXPENDITURE OF GROUP IS EXPECTED
TO
INCREASE SUBSTANTIALLY IN COMING YEARS
    * LEE'S PHARMACEUTICAL HOLDINGS - GROUP DECIDED TO GRADUALLY
SEPARATE RESEARCH AND DEVELOPMENT ACTIVITIES IN ONCOLOGY AND
OPHTHALMOLOGY FROM ITS CORE REVENUE STREAM

Source text for Eikon:  ID:nHKS5HgShS 
Further company coverage:  0950.HK 

 ((Reuters.Briefs@thomsonreuters.com;))